cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Jazz Pharmaceuticals Plc
25 own
22 watching
Current Price
$107.32
$-0.3
(-0.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
7,725.59M
52-Week High
52-Week High
137.39000
52-Week Low
52-Week Low
99.06000
Average Volume
Average Volume
0.55M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
199.9066
iconMarket Capitalization7,725.59M
icon52-Week High137.39000
icon52-Week Low99.06000
iconAverage Volume0.55M
iconDividend Yield--
iconP/E Ratio199.9066
What does the Jazz Pharmaceuticals Plc do?
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinson's disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Read More
How much money does Jazz Pharmaceuticals Plc make?
News & Events about Jazz Pharmaceuticals Plc.
Globe Newswire
1 year ago
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Zug, Switzerland & Egham, UK 21 June 2023 Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products...
Ticker Report
1 year ago
Jazz Pharmaceuticals plc (NASDAQ:JAZZ Get Rating) has received an average recommendation of Buy from the nine ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, five have issued a buy ...
Ticker Report
1 year ago
Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ Get Rating) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 176,388 shares of the ...
Zolmax
1 year ago
Pinnacle Associates Ltd. cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ Get Rating) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,375 shares of the specialty pharmaceutical companys stock after selling 100 shares during the ...
Ticker Report
1 year ago
Jazz Pharmaceuticals (NASDAQ:JAZZ Get Rating) had its target price boosted by The Goldman Sachs Group from $190.00 to $212.00 in a research report report published on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the specialty pharmaceutical company...
Frequently Asked Questions
Frequently Asked Questions
What is Jazz Pharmaceuticals Plc share price today?
plus_minus_icon
Can Indians buy Jazz Pharmaceuticals Plc shares?
plus_minus_icon
How can I buy Jazz Pharmaceuticals Plc shares from India?
plus_minus_icon
Can Fractional shares of Jazz Pharmaceuticals Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Jazz Pharmaceuticals Plc stocks?
plus_minus_icon
What is today’s traded volume of Jazz Pharmaceuticals Plc?
plus_minus_icon
What is today’s market capitalisation of Jazz Pharmaceuticals Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Jazz Pharmaceuticals Plc?
plus_minus_icon
What percentage is Jazz Pharmaceuticals Plc down from its 52-Week High?
plus_minus_icon
What percentage is Jazz Pharmaceuticals Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$107.32
$-0.3
(-0.28%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$38.06
$0.26 (0.69 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$87.54
$0.06 (0.07 %)
Catalent, Inc.
Catalent, Inc.
$60.95
$0.20 (0.33 %)
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc.
$73.25
$0.86 (1.19 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$38.06
$0.26 (0.69 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$87.54
$0.06 (0.07 %)
Catalent, Inc.
Catalent, Inc.
$60.95
$0.20 (0.33 %)
Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc.
$73.25
$0.86 (1.19 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00